MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.Read More
Recent Press Releases
07/18/19MyoKardia Announces HCM Program Updates: Accelerates Timing for Mavacamten Topline Phase 3 Data; Re-acquires U.S. Royalty Rights to HCM Programs from Sanofi
06/24/19MyoKardia Publishes Data in Nature Digital Medicine Showing Potential of Wrist-Worn Biosensor to Screen for Hypertrophic Cardiomyopathy
NASDAQ GS | MYOK (Common Stock)
$53.52 - 0.03
10/26/184:00 p.m. ETData provided by Nasdaq. Minimum 15 minutes delayed.
There are currently no events scheduled.